309 related articles for article (PubMed ID: 12608887)
21. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
Trigg ME; Higa GM
J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
[TBL] [Abstract][Full Text] [Related]
22. 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment.
Aapro M
Oncology; 2005; 69(2):97-109. PubMed ID: 16131816
[TBL] [Abstract][Full Text] [Related]
23. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
24. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
Siddique R; Hafiz MG; Rokeya B; Jamal CY; Islam A
Mymensingh Med J; 2011 Oct; 20(4):680-8. PubMed ID: 22081189
[TBL] [Abstract][Full Text] [Related]
25. Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Oddby-Muhrbeck E; Öbrink E; Eksborg S; Rotstein S; Lönnqvist PA
Acta Anaesthesiol Scand; 2013 Jul; 57(6):749-53. PubMed ID: 23281590
[TBL] [Abstract][Full Text] [Related]
26. Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children.
Dupuis LL; Nathan PC
Paediatr Drugs; 2003; 5(9):597-613. PubMed ID: 12956617
[TBL] [Abstract][Full Text] [Related]
27. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
28. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Cunningham RS
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
[TBL] [Abstract][Full Text] [Related]
29. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
Herrstedt J
Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
[TBL] [Abstract][Full Text] [Related]
30. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
[TBL] [Abstract][Full Text] [Related]
32. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Aksoylar S; Akman SA; Ozgenç F; Kansoy S
Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
[TBL] [Abstract][Full Text] [Related]
33. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?
Gan TJ
CNS Drugs; 2005; 19(3):225-38. PubMed ID: 15740177
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy-induced nausea and vomiting: clinician and patient perspectives.
Schwartzberg LS
J Support Oncol; 2007 Feb; 5(2 Suppl 1):5-12. PubMed ID: 17366928
[TBL] [Abstract][Full Text] [Related]
36. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
37. 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile.
Goodin S; Cunningham R
Oncologist; 2002; 7(5):424-36. PubMed ID: 12401905
[TBL] [Abstract][Full Text] [Related]
38. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
[TBL] [Abstract][Full Text] [Related]
39. [An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
Tsukagoshi S; Ohta J; Taguchi T
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2276-81. PubMed ID: 8259839
[TBL] [Abstract][Full Text] [Related]
40. Risks and benefits of drugs used in the management of postoperative nausea and vomiting.
Sung YF
Drug Saf; 1996 Mar; 14(3):181-97. PubMed ID: 8934580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
